Clinical Trial Update: HC010 in First-line PD-L1 Positive Advanced NSCLC Patients [Phase 2]

View source ↗

Summary

Phase 2 clinical trial HC010 is recruiting in first-line PD-L1 positive advanced non-small cell lung cancer patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• HC010

Snippet

Sponsor: HC Biopharma Inc. | Conditions: NSCLC | Phase 2 | Status: RECRUITING